Anti-BCMA antibodies in the future management of multiple myeloma

Expert Review of Anticancer Therapy
Maria GavriatopoulouEvangelos Terpos

Abstract

B-cell maturation antigen (BCMA) belongs to the tumor necrosis factor receptor family and is expressed on late B-cells and plasma cells. Serum BCMA is elevated in patients with multiple myeloma (MM) and chronic lymphocytic leukemia (CLL), and might represent a novel prognostic and monitoring tool. Serum BCMA levels can predict both progression free survival (PFS) and overall survival (OS). Several therapeutic strategies are currently under investigation including BCMA-directed monoclonal Abs (either naked or with drug conjugates, and bispecific Abs) and cellular T-cell therapies (chimeric antigen receptor T-cells) with impressive clinical results. Areas covered: This review aims to present the mechanisms of action and the available data on efficacy and safety of therapies targeting BCMA. Expert opinion: The preliminary preclinical and clinical results from the phase 1 and 2 studies have demonstrated significant activity of the anti-BCMA therapeutic strategies. The main toxicities induced include Cytokine Release Syndrome (CRS) and ocular toxicity. The management of these adverse events remains currently an issue of controversy.

References

Jun 8, 1999·The Journal of Experimental Medicine·P SchneiderJ Tschopp
Jul 26, 2000·Proceedings of the National Academy of Sciences of the United States of America·H B Shu, H Johnson
Jul 3, 2002·Nature Reviews. Immunology·Fabienne Mackay, Jeffrey L Browning
Jun 11, 2003·The Journal of Biological Chemistry·Marc PelletierYen-Ming Hsu
Jul 17, 2003·The Journal of Clinical Investigation·Danielle T AveryStuart G Tangye
May 30, 2006·Trends in Immunology·Clark L AndersonSudhasri Mohanty
Nov 21, 2007·Molecular Cancer Therapeutics·Maureen C RyanPaul J Carter
Jul 19, 2012·British Journal of Haematology·Eric SanchezJames R Berenson
Jan 25, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Robert O CarpenterJames N Kochenderfer
Apr 1, 2015·Journal of the American Chemical Society·Nitya S RamadossTravis S Young
Mar 11, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Eric SanchezJames R Berenson
Mar 6, 2018·Expert Review of Molecular Diagnostics·Eric SanchezJames Berenson

❮ Previous
Next ❯

Citations

Jan 17, 2020·Expert Opinion on Biological Therapy·Ioannis Ntanasis-StathopoulosEvangelos Terpos
May 30, 2020·Scandinavian Journal of Immunology·Deming Feng, Jian Sun
Feb 9, 2020·International Journal of Hematology·Hiroyuki Takamatsu
Jul 27, 2021·Frontiers in Oncology·Alessandra RomanoNicola Giuliani

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

B cell Differentiation

Depending on the signal received through the B cell receptor and other receptors, B cells differentiate into follicular or marginal zone B cells. Here is the latest research pertaining to this differentiation process.

© 2022 Meta ULC. All rights reserved